Article Per Year (5 Year)
p-Index From 2019 - 2024
0.23
P-Index
This Author published in this journals
All Journal Kartika : Jurnal Ilmiah Farmasi
Nur Sidik Cahyono
Program Studi Magister Farmasi, Fakultas Farmasi, Universitas Jenderal Achmad Yani, Cimahi, Indonesia
Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Social Sciences

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
EFEKTIVITAS-BIAYA PENGGUNAAN BEVACIZUMAB DAN RANIBIZUMAB SEBAGAI ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PADA PASIEN DENGAN GANGGUAN MATA: TINJAUAN SISTEMATIS Nur Sidik Cahyono; Elin Yulinah Sukandar
Kartika : Jurnal Ilmiah Farmasi Vol 9 No 1 (2024)
Publisher : Fakultas Farmasi Universitas Jenderal Achmad Yani, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.26874/kjif.v9i1.658

Abstract

Anti-vascular endothelial growth factor (VEGF) given by intravitreal injection can be used to treat patients with eye disorders. The anti-VEGF drugs used include bevacizumab, ranibizumab, aflibercept, and brolucizumab. These drugs are high-cost drugs, so the cost-effectiveness of each drug must be considered in order to save on treatment costs. This systematic review aims to provide a comprehensive picture of the cost-effectiveness of bevacizumab and ranibizumab. The databases used to identify relevant studies are PubMed, Science Direct and Google Scholar. This research is limited to randomized control trials (RCT), clinical trials, and research articles, studies that explain the cost-effectiveness of intravitreal injections of bevacizumab and ranibizumab and other drugs as anti-VEGF for patients with eye disorders, as well as articles in English. Electronic data-based searches resulted in 2414 articles; 27 articles were selected that had full text access and discussed the cost-effectiveness of ranibizumab or bevacizumab, but only 12 articles suitable for inclusion were considered. Bevacizumab is more cost-effective than ranibizumab.
Co-Authors Elin Yulinah Sukandar